Cansino Biotech (06185) announced interim results, net loss of 721,000 yuan, narrowing by 94.65% year-on-year

According to the Zhitong Finance App, Cansino Biotech (06185) announced its 2026 interim results, with revenue of about 547 million yuan, up 46.1% year on year; gross profit of about 413 million yuan, up 39.4% year on year; net loss of 721,000 yuan, narrowing 94.65% year on year.

According to the announcement, the increase in revenue is mainly due to: (i) With effect from January 1, 2026, domestic sales of vaccine products will no longer apply the 3% levy rate under the simple levy method for biological products, and will be adjusted to a 13% value-added tax rate under the general taxation system. In the context of the VAT rate adjustment, as the first quadrivalent influenza conjugate vaccine in China, MANHEXIN® continued to grow in sales volume compared to the same period in 2025 and maintained its dominant position in the market; at the same time, the successful launch of the 13-valent pneumococcal conjugate vaccine Eupexin® also brought considerable revenue, offsetting the negative effects related to VAT, which combined led to an upward trend in domestic vaccine product sales revenue; and (ii) the international technology transfer and vaccine intermediates sales business accounted for a significant share of the Group's revenue during the reporting period.

During the reporting period, the group achieved overseas revenue of about 152 million yuan, which achieved significant growth, mainly due to the remarkable expansion of the international vaccine intermediates sales market and the continuous expansion of international technology transfer and the scale of the CDMO business.